ABG
EPRX

Ally Bridge Group’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Ally Bridge Group’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.67M Sell
252,175
-408,200
-62% -$2.81M 1.47% 23
2026
Q1 		$4.78M Buy
660,375
+262,480
+66% +$2.11M 3.86% 13
2025
Q4 		$3M Sell
397,895
-517,105
-57% -$3.19M 3.13% 12
2025
Q3 		$5.4M Buy
+915,000
New +$4.98M 3.29% 12

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Ally Bridge Group's EPRX Position: Q2 2026 in Review

Ally Bridge Group reduced its Eupraxia Pharmaceuticals (EPRX) stake by 62% in Q2 2026, selling an estimated $2.81M and leaving 252,175 shares worth $1.67M. The position accounts for 1.47% of the portfolio, ranked #23.

Ally Bridge Group first reported a position in EPRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $5.4M in Q3 2025. 68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Ally Bridge Group held 252,175 shares of Eupraxia Pharmaceuticals worth $1.67M as of Q2 2026.
  • Ally Bridge Group sold 408,200 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $2.81M.
  • Eupraxia Pharmaceuticals made up 1.47% of Ally Bridge Group's portfolio in Q2 2026, its #23 holding.
  • Ally Bridge Group first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Ally Bridge Group's Eupraxia Pharmaceuticals position peaked at $5.4M in Q3 2025.
  • 68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.